BLSM ▲ +6.9% - BlossomHill Therapeutics, Inc. $BLSM - BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer BlossomHill Therapeutics rose 6.9% following the presentation of updated Phase 1/2 trial data for its EGFR inhibitor BH-30643, which demonstrated encouraging anti-tumor activity in patients with EGFR C797S-positive non-small cell lung cancer. The positive clinical readout at the IASLC World Conference on Lung Cancer supported investor optimism about the candidate's therapeutic potential in this resistant mutation subset. 15-SEP-2026 07:00 AM ET